Effectiveness of liraglutide in the treatment of adolescent obesity.

Ruiz Pons M, Gutiérrez Vilar M, García Zurita C, Fuentes Ferrer ME, Pérez Rodríguez A, Rosado Alonso C

Anales de pediatria10 Jul 2025Cited by 3 (Europe PMC)

PMID40645873DOI10.1016/j.anpede.2025.503856PepBankPUB-40645873

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In an observational comparison of adolescents with obesity, liraglutide plus lifestyle modification was associated with a greater BMI z-score decrease than lifestyle modification alone (-1.09 [SD 0.24] vs -0.10 [SD 0.25]; P=.001).
In plain wordsIn adolescents with obesity, liraglutide plus lifestyle changes was linked to a larger BMI z-score decrease than lifestyle changes alone.
Peptide
Liraglutide
Outcome
DecreaseBMI z score
Study
n = 62
Comparator
Lifestyle modification alone
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6.9 monthsAs given in this study (human).
Measurements
Mean BMI-z change
−1.09
liraglutide plus lifestyle
BMI-z change SD
0.24
liraglutide plus lifestyle
Mean BMI-z change
−0.1
lifestyle controls
BMI-z change SD
0.25
lifestyle controls
Source sentences
Summary
In the intervention group, the BMI z score decreased significantly (mean, -1.09 [SD, 0.24] vs -0.10 [SD, 0.25] in controls; P=.001).
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
Report a problemFND-4064587301
02HumanObservational studyEfficacy outcome
In an observational comparison of adolescents with obesity, liraglutide plus lifestyle modification was associated with more patients achieving at least 5% BMI reduction than controls (48.4% vs 3%; P<.05).
In plain wordsIn adolescents with obesity, adding liraglutide was linked to more patients reaching 5% BMI reduction than lifestyle changes alone.
Peptide
Liraglutide
Outcome
IncreaseBMI reduction of 5% or greater
Study
n = 62
Comparator
Lifestyle modification alone
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6.9 monthsAs given in this study (human).
Measurements
Proportion
48.4%
liraglutide plus lifestyle modification
Proportion
3%
controls
Source sentences
Summary
This corresponded to a BMI reduction of 5% or greater in 48.4% of patients and 10% or greater in 29%, compared to 3% and 1%, respectively, in the control group (P<.05).
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
Report a problemFND-4064587302
03HumanObservational studyEfficacy outcome
In an observational comparison of adolescents with obesity, liraglutide plus lifestyle modification was associated with more patients achieving at least 10% BMI reduction than controls (29% vs 1%; P<.05).
In plain wordsIn adolescents with obesity, adding liraglutide was linked to more patients reaching 10% BMI reduction than lifestyle changes alone.
Peptide
Liraglutide
Outcome
IncreaseBMI reduction of 10% or greater
Study
n = 62
Comparator
Lifestyle modification alone
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6.9 monthsAs given in this study (human).
Measurements
Proportion
29%
liraglutide plus lifestyle modification
Proportion
1%
controls
Source sentences
Summary
This corresponded to a BMI reduction of 5% or greater in 48.4% of patients and 10% or greater in 29%, compared to 3% and 1%, respectively, in the control group (P<.05).
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
Report a problemFND-4064587303

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In the adolescent obesity cohort comparing liraglutide/lifestyle with lifestyle alone, weight loss was reportedly maintained at six-month follow-up; the reported weight-loss maintenance result did not identify a native-specific arm estimate or exact reference.
In plain wordsIn adolescent obesity cohorts including liraglutide, weight loss was reportedly maintained at six-month follow-up; the exact group comparison was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedWeight loss at follow-up
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
The weight loss was maintained at six months of follow-up (T3).
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064587304
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In the adolescent obesity cohort comparing liraglutide/lifestyle with lifestyle alone, insulin levels decreased; the reported insulin levels result did not identify a native-specific arm estimate or exact reference.
In plain wordsIn adolescent obesity cohorts including liraglutide, insulin levels decreased; the exact group comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseInsulin levels
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was a significant reduction in insulin levels, the HOMA-IR, triglyceride levels, systolic hypertension (HTN), and the number of prediabetic patients.
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064587305
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In the adolescent obesity cohort comparing liraglutide/lifestyle with lifestyle alone, HOMA-IR decreased; the reported HOMA-IR result did not identify a native-specific arm estimate or exact reference.
In plain wordsIn adolescent obesity cohorts including liraglutide, HOMA-IR decreased; the exact group comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseHOMA-IR
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was a significant reduction in insulin levels, the HOMA-IR, triglyceride levels, systolic hypertension (HTN), and the number of prediabetic patients.
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064587306
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In the adolescent obesity cohort comparing liraglutide/lifestyle with lifestyle alone, triglycerides decreased; the reported triglycerides result did not identify a native-specific arm estimate or exact reference.
In plain wordsIn adolescent obesity cohorts including liraglutide, triglycerides decreased; the exact group comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
There was a significant reduction in insulin levels, the HOMA-IR, triglyceride levels, systolic hypertension (HTN), and the number of prediabetic patients.
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064587307
08HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In the adolescent obesity cohort comparing liraglutide/lifestyle with lifestyle alone, systolic hypertension decreased; the reported systolic hypertension result did not identify a native-specific arm estimate or exact reference.
In plain wordsIn adolescent obesity cohorts including liraglutide, systolic hypertension decreased; the exact group comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseSystolic hypertension
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
There was a significant reduction in insulin levels, the HOMA-IR, triglyceride levels, systolic hypertension (HTN), and the number of prediabetic patients.
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064587308
09HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In the adolescent obesity cohort comparing liraglutide/lifestyle with lifestyle alone, the number of participants with prediabetes decreased; the reported prediabetic participant count result did not identify a native-specific arm estimate or exact reference.
In plain wordsIn adolescent obesity cohorts including liraglutide, the number of participants with prediabetes decreased; the exact group comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreasePrediabetes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
There was a significant reduction in insulin levels, the HOMA-IR, triglyceride levels, systolic hypertension (HTN), and the number of prediabetic patients.
4 context sentences(design, population, supporting numbers)
Summary · context
Retrospective observational study of 62 adolescents (12-18 years) with a body mass index (BMI) at or above the 95th percentile.
Summary · context
The intervention group (n=31) received liraglutide plus LM, while controls (n=31) matched for age, sex and treatment duration were managed with LM alone.
Summary · context
We analyzed anthropometric, cardiovascular and body composition variables at three time points: baseline (T1), end of treatment (T2: mean, 6.9 months; SD, 4.7), and follow-up (T3: mean, 12.5 months; SD, 4.9 months).
Summary · context
Comparisons between groups were performed using adjusted analysis of covariance model for changes in quantitative variables and logistic regression for BMI reductions of 5% or greater and 10% or greater.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4064587309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.